Abstract
Many anti-infectives inhibit the synthesis of bacterial proteins, but none selectively inhibits their degradation. Most anti-infectives kill replicating pathogens, but few preferentially kill pathogens that have been forced into a non-replicating state by conditions in the host. To explore these alternative approaches we sought selective inhibitors of the proteasome of Mycobacterium tuberculosis. Given that the proteasome structure is extensively conserved, it is not surprising that inhibitors of all chemical classes tested have blocked both eukaryotic and prokaryotic proteasomes, and no inhibitor has proved substantially more potent on proteasomes of pathogens than of their hosts. Here we show that certain oxathiazol-2-one compounds kill non-replicating M. tuberculosis and act as selective suicide-substrate inhibitors of the M. tuberculosis proteasome by cyclocarbonylating its active site threonine. Major conformational changes protect the inhibitor-enzyme intermediate from hydrolysis, allowing formation of an oxazolidin-2-one and preventing regeneration of active protease. Residues outside the active site whose hydrogen bonds stabilize the critical loop before and after it moves are extensively non-conserved. This may account for the ability of oxathiazol-2-one compounds to inhibit the mycobacterial proteasome potently and irreversibly while largely sparing the human homologue.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baumeister, W., Walz, J., Zuhl, F. & Seemuller, E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 92, 367–380 (1998)
Kropff, M. et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br. J. Haematol. 138, 330–337 (2007)
Glenn, R. J. et al. Trypanocidal effect of α′, β′-epoxyketones indicates that trypanosomes are particularly sensitive to inhibitors of proteasome trypsin-like activity. Int. J. Antimicrob. Agents 24, 286–289 (2004)
Darwin, K. H. et al. The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science 302, 1963–1966 (2003)
Raviglione, M. C. & Smith, I. M. XDR tuberculosis–implications for global public health. N. Engl. J. Med. 356, 656–659 (2007)
Corbett, E. L. et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163, 1009–1021 (2003)
Restrepo, B. I. Convergence of the tuberculosis and diabetes epidemics: renewal of old acquaintances. Clin. Infect. Dis. 45, 436–438 (2007)
Pearce, M. J. et al. Ubiquitin-like protein involved in the proteasome pathway of Mycobacterium tuberculosis . Science 322, 1104–1107 (2008)
Burns, K. E. et al. Proteasomal protein degradation in mycobacteria is dependent upon a prokaryotic ubiquitin-like protein. J. Biol. Chem. 284, 3069–3075 (2009)
Gandotra, S. et al. In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice. Nature Med. 13, 1515–1520 (2007)
Borissenko, L. & Groll, M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem. Rev. 107, 687–717 (2007)
Lin, G. et al. Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates. J. Biol. Chem. 283, 34423–34431 (2008)
Kisselev, A. F. & Goldberg, A. L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8, 739–758 (2001)
Hu, G. et al. Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate. Mol. Microbiol. 59, 1417–1428 (2006)
Lin, G. et al. Mycobacterium tuberculosis prcBA genes encode a gated proteasome with broad oligopeptide specificity. Mol. Microbiol. 59, 1405–1416 (2006)
Bryk, R. et al. Selective killing of nonreplicating mycobacteria. Cell Host Microbe 3, 137–145 (2008)
Huth, J. R. et al. Toxicological evaluation of thiol-reactive compounds identified using a La assay to detect reactive molecules by nuclear magnetic resonance. Chem. Res. Toxicol. 20, 1752–1759 (2007)
Copp, L. J. in Enzyme Kinetics: A Modern Approach (ed. Marangoni, A. G.) Ch. 13 158–173 (Wiley, 2003)
Russo, A., Chandramouli, N., Zhang, L. & Deng, H. T. Reductive glutaraldehydation of amine groups for identification of protein N-termini. J. Proteome Res. 7, 4178–4182 (2008)
Lu, L. Q. et al. A new entry to cascade organocatalysis: reactions of stable sulfur ylides and nitroolefins sequentially catalyzed by thiourea and DMAP. J. Am. Chem. Soc. 130, 6946–6948 (2008)
Rajca, A., Grobelny, D., Witek, S. & Zbirovsky, M. 5-Aryl-2-oxo-1,2,4-oxathiazoles as cyclocarbonylating agents for 2-aminoalcohols and 1,2-diamines. Synthesis 12, 1032–1033 (1983)
MacMicking, J. D. et al. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl Acad. Sci. USA 94, 5243–5248 (1997)
Walsh, C. Where will new antibiotics come from? Nature Rev. Microbiol. 1, 65–70 (2003)
Hu, Y. M. et al. Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. FEMS Microbiol. Lett. 158, 139–145 (1998)
Copeland, R. A. in Enzymes: a Practical Introduction to Structure, Mechanism, and Data Analysis Chs 9–10 305–349 (Wiley, 2000)
Otwinoswki, Z. & Minor, W. in Methods in Enzymology (eds Carter, C. W. Jr & Sweet, R. M.) 307–326 (Academic, 1997)
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Cryst. 40, 658–674 (2007)
Brünger, A. T. et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D 54, 905–921 (1998)
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126–2132 (2004)
Adams, P. D. et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D 58, 1948–1954 (2002)
Acknowledgements
S. Eswaramoorthy helped with crystallography software, C. Lipinski, C. Walsh and M. Fischbach proposed reaction mechanisms, and C. Karan assisted with screening. S. Ehrt and S. Gandotra performed some bactericidal assays, C. Tsu and L. Dick donated a fluorimeter and J. Blanchard provided BlaC. Supported by NIH PO1-AI056293, NIH R01AI070285 and the Milstein Program in Chemical Biology of Infectious Diseases. X-ray diffraction data were collected at beamline X6A, X25 and X29 in the National Synchrotron Light Source, a facility supported by the US DOE and NIH. The Department of Microbiology and Immunology is supported by the William Randolph Hearst Foundation.
Author Contributions G.L. purified recombinant proteasome, conducted the screen, designed new oxathiazol-2-one compounds and performed most of the assays. D.L. and H.L. purified and crystallized recombinant proteasomes and solved their structures. L.P.S.C. helped analyse kinetics. H.D. performed mass spectrometry. H.T. synthesized oxathiazol-2-one compounds under the supervision of J.D.W.; G.V. studied human macrophages. K.W. conducted studies with viable M. tuberculosis. J.S. and T.C. performed kinetic, bactericidal and cytotoxicity experiments. C.N. organized the effort and helped design and interpret experiments. C.N., G.L. and H.L. wrote the paper.
Author information
Authors and Affiliations
Corresponding authors
Supplementary information
Supplementary Information
This file contains Supplementary Methods, Supplementary Tables S1-S5 and Supplementary Figures S1- S9 with Legends. (PDF 3274 kb)
Rights and permissions
About this article
Cite this article
Lin, G., Li, D., de Carvalho, L. et al. Inhibitors selective for mycobacterial versus human proteasomes. Nature 461, 621–626 (2009). https://doi.org/10.1038/nature08357
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature08357
This article is cited by
-
A novel graph convolutional neural network for predicting interaction sites on protein kinase inhibitors in phosphorylation
Scientific Reports (2022)
-
Tuberculosis: current scenario, drug targets, and future prospects
Medicinal Chemistry Research (2021)
-
Active metabolism unmasks functional protein–protein interactions in real time in-cell NMR
Communications Biology (2020)
-
Bacterial proteases, untapped antimicrobial drug targets
The Journal of Antibiotics (2017)
-
Caught in Action: Selecting Peptide Aptamers Against Intrinsically Disordered Proteins in Live Cells
Scientific Reports (2015)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.